AU2013259381B2 - Cell wall protein CwpV (CD0514) as a diagnostic marker for Clostridium difficile ribotype 027 - Google Patents
Cell wall protein CwpV (CD0514) as a diagnostic marker for Clostridium difficile ribotype 027 Download PDFInfo
- Publication number
- AU2013259381B2 AU2013259381B2 AU2013259381A AU2013259381A AU2013259381B2 AU 2013259381 B2 AU2013259381 B2 AU 2013259381B2 AU 2013259381 A AU2013259381 A AU 2013259381A AU 2013259381 A AU2013259381 A AU 2013259381A AU 2013259381 B2 AU2013259381 B2 AU 2013259381B2
- Authority
- AU
- Australia
- Prior art keywords
- cwpv
- ribotype
- difficile
- antibodies
- determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims description 42
- 108090000623 proteins and genes Proteins 0.000 title description 10
- 102000004169 proteins and genes Human genes 0.000 title description 6
- 210000002421 cell wall Anatomy 0.000 title description 5
- 239000003550 marker Substances 0.000 title description 5
- 238000000034 method Methods 0.000 claims description 27
- 238000002965 ELISA Methods 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 230000002550 fecal effect Effects 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 238000003018 immunoassay Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000004069 differentiation Effects 0.000 abstract description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- ZVGNESXIJDCBKN-UUEYKCAUSA-N fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 description 6
- ZVGNESXIJDCBKN-WUIGKKEISA-N R-Tiacumicin B Natural products O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC1=CC=CC[C@H](O)C(C)=C[C@@H]([C@H](C(C)=CC(C)=CC[C@H](OC1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-WUIGKKEISA-N 0.000 description 5
- 229960000628 fidaxomicin Drugs 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 229920001410 Microfiber Polymers 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000003658 microfiber Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 101800001415 Bri23 peptide Proteins 0.000 description 3
- 101800000655 C-terminal peptide Proteins 0.000 description 3
- 102400000107 C-terminal peptide Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 2
- 231100000033 toxigenic Toxicity 0.000 description 2
- 230000001551 toxigenic effect Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 101710188314 Protein V Proteins 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 229940004552 dificid Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 101150070420 gyrA gene Proteins 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 201000002516 toxic megacolon Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645964P | 2012-05-11 | 2012-05-11 | |
| US61/645,964 | 2012-05-11 | ||
| US13/889,670 US9133527B2 (en) | 2012-05-11 | 2013-05-08 | Cell wall protein CwpV (CD0514) as a diagnostic marker for Clostridium difficile ribotype 027 |
| US13/889,670 | 2013-05-08 | ||
| PCT/US2013/040399 WO2013170065A1 (en) | 2012-05-11 | 2013-05-09 | Cell wall protein cwpv (cd0514) as a diagnostic marker for clostridium difficile ribotype 027 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013259381A1 AU2013259381A1 (en) | 2014-12-04 |
| AU2013259381B2 true AU2013259381B2 (en) | 2018-08-16 |
Family
ID=49548891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013259381A Active AU2013259381B2 (en) | 2012-05-11 | 2013-05-09 | Cell wall protein CwpV (CD0514) as a diagnostic marker for Clostridium difficile ribotype 027 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9133527B2 (enExample) |
| EP (1) | EP2847590B1 (enExample) |
| JP (1) | JP6165238B2 (enExample) |
| AU (1) | AU2013259381B2 (enExample) |
| CA (1) | CA2872482C (enExample) |
| ES (1) | ES2628334T3 (enExample) |
| NZ (1) | NZ702383A (enExample) |
| WO (1) | WO2013170065A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI126289B (en) * | 2014-12-19 | 2016-09-15 | Mobidiag Ltd | Method for detecting the presence of a hypervirulent strain of Clostridium difficile |
| CN106814189B (zh) * | 2016-12-20 | 2018-10-26 | 成都金思唯生物技术有限公司 | 一种检测艰难梭菌的试剂盒及其用途 |
| US20190211377A1 (en) * | 2016-12-22 | 2019-07-11 | Roche Molecular Systems, Inc. | Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965375A (en) * | 1997-04-04 | 1999-10-12 | Biosite Diagnostics | Diagnostic tests and kits for Clostridium difficile |
| ES2564169T3 (es) * | 2004-11-24 | 2016-03-18 | Techlab, Inc. | Dispositivo y método para la detección de analitos |
| CA2714720A1 (en) * | 2008-02-28 | 2009-09-03 | 3M Innovative Properties Company | Antibodies to clostridium difficile spores and uses thereof |
| ATE478967T1 (de) * | 2008-09-16 | 2010-09-15 | Oesterreichische Agentur Fuer | Pcr-ribotyping |
| US20120028819A1 (en) * | 2009-04-07 | 2012-02-02 | Koninklijke Philips Electronics N.V. | Method for the detection and characterization of a toxinogenic clostridium difficile strain |
| US8889363B2 (en) | 2009-07-27 | 2014-11-18 | Biodics | Method for the detection and identification of a variant C. difficile strain in a sample |
| JP5591332B2 (ja) * | 2009-07-27 | 2014-09-17 | バイオディクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 試料中における変異したｃ．ディフィシル菌株を検出および同定するための方法 |
| US20120276060A1 (en) | 2011-04-29 | 2012-11-01 | Techlab, Inc. | Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease |
| US8790880B2 (en) | 2011-09-26 | 2014-07-29 | Techlab, Inc. | Cysteine protease Cwp84 (CD2787) as a diagnostic marker for Clostridium difficile |
-
2013
- 2013-05-08 US US13/889,670 patent/US9133527B2/en active Active
- 2013-05-09 JP JP2015511712A patent/JP6165238B2/ja active Active
- 2013-05-09 AU AU2013259381A patent/AU2013259381B2/en active Active
- 2013-05-09 CA CA2872482A patent/CA2872482C/en active Active
- 2013-05-09 WO PCT/US2013/040399 patent/WO2013170065A1/en not_active Ceased
- 2013-05-09 ES ES13787811.2T patent/ES2628334T3/es active Active
- 2013-05-09 EP EP13787811.2A patent/EP2847590B1/en active Active
- 2013-05-09 NZ NZ702383A patent/NZ702383A/en unknown
Non-Patent Citations (1)
| Title |
|---|
| REYNOLDS, CB. ET AL., "The Clostridium Difficile Cell Wall Protein CwpV Is Antigenically Variable Between Strains, But Exhibits Conserved Aggregation-Promoting Function.", PLOS PATHOGENS., (2011-04-21), vol. 7, no. 4, pages 1 - 14 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US9133527B2 (en) | 2015-09-15 |
| EP2847590B1 (en) | 2017-04-05 |
| CA2872482A1 (en) | 2013-11-14 |
| CA2872482C (en) | 2017-10-31 |
| WO2013170065A1 (en) | 2013-11-14 |
| JP6165238B2 (ja) | 2017-07-19 |
| NZ702383A (en) | 2016-12-23 |
| JP2015517658A (ja) | 2015-06-22 |
| US20130302813A1 (en) | 2013-11-14 |
| EP2847590A1 (en) | 2015-03-18 |
| AU2013259381A1 (en) | 2014-12-04 |
| ES2628334T3 (es) | 2017-08-02 |
| EP2847590A4 (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sanchez-Hurtado et al. | Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls | |
| Reller et al. | Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile | |
| Carroll et al. | Laboratory tests for the diagnosis of Clostridium difficile | |
| Siboo et al. | Characterization of the accessory Sec system of Staphylococcus aureus | |
| Stevens et al. | Clostridium | |
| Yoldaş et al. | A diagnostic algorithm for the detection of Clostridium difficile-associated diarrhea | |
| Furukawa et al. | Characterization of Propionibacterium acnes isolates from sarcoid and non-sarcoid tissues with special reference to cell invasiveness, serotype, and trigger factor gene polymorphism | |
| Pastorello et al. | EsiB, a novel pathogenic Escherichia coli secretory immunoglobulin A-binding protein impairing neutrophil activation | |
| JP5591332B2 (ja) | 試料中における変異したｃ．ディフィシル菌株を検出および同定するための方法 | |
| Barbut et al. | Usefulness of simultaneous detection of toxin A and glutamate dehydrogenase for the diagnosis of Clostridium difficile-associated diseases | |
| Siu et al. | Development of a colloidal gold-based immunochromatographic strip for rapid detection of Klebsiella pneumoniae serotypes K1 and K2 | |
| AU2013259381B2 (en) | Cell wall protein CwpV (CD0514) as a diagnostic marker for Clostridium difficile ribotype 027 | |
| Leeming et al. | Diagnosis of invasive pneumococcal infection by serotype-specific urinary antigen detection | |
| Matsui et al. | Immunochromatographic detection of the group B streptococcus antigen from enrichment cultures | |
| Anwar et al. | Low-toxin Clostridioides difficile RT027 strains exhibit robust virulence | |
| Kawada et al. | Evaluation of a simultaneous detection kit for the glutamate dehydrogenase antigen and toxin A/B in feces for diagnosis of Clostridium difficile infection | |
| Miyashita et al. | Antibody responses of Chlamydophila pneumoniae pneumonia: Why is the diagnosis of C. pneumoniae pneumonia difficult? | |
| Cooper et al. | ELISA and immuno–polymerase chain reaction assays for the sensitive detection of melioidosis | |
| Ataee et al. | Staphylococcal enterotoxin a detection from rheumatoid arthritis patients’ blood and synovial fluid | |
| Monaghan et al. | High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection | |
| US8889363B2 (en) | Method for the detection and identification of a variant C. difficile strain in a sample | |
| US8591899B2 (en) | Diagnosis of Bacillus anthracis infection based on detection of bacterial secreted biomarkers | |
| Noorbakhsh et al. | Identification of bacterial antigens and super antigens in synovial fluid of patients with arthritis: a cross sectional study | |
| Kawabata et al. | Exfoliative toxin detection using reversed passive latex agglutination: clinical and epidemiologic applications | |
| Murthy et al. | Evaluation of the diagnostic potential of region of deletion-1–encoded antigen culture filtrate protein-10 in pulmonary tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |